



A large body of data indicates that multiple sclerosis (MS) is an autoimmune disease which is initiated by
CD4 + T-helper 1 (Th1) and Th17 cells that are reactive against proteins in the myelin sheath. MS typically
begins with a relapsing-remitting course, punctuated by clinical exacerbations associated with the development
of focal inflammatory lesions in central nervous system white matter, followed by a secondary progressive (SP)
phase, characterized by a gradual accumulation of neurological disability associated with widespread microglial
activation and axonal loss. The molecular and cellular basis for this transition is unclear, and the role of
inflammation during the SP stage is a subject of active debate. As of now, no immunological biomarkers have
been identified in MS that are predictive of the clinical course or therapeutic responsiveness to disease-
modifying agents, or that correlate with new lesion development, cumulative lesion load, or degree of disability.
The discovery of such biomarkers would greatly facilitate clinical management and provide power for smaller
and shorter clinical trials. In this article, we discuss the literature on immunological biomarkers in MS with a
focus on stage-specific differences and similarities.
Introduction
Multiple sclerosis (MS), a multifocal demyelinatingdisease of the central nervous system (CNS), is the
most common cause of nontraumatic disability among
young adults in the Western hemisphere. It typically pres-
ents with a relapsing remitting course, in which discrete
episodes of neurological symptoms (relapses) are separated
by clinically quiescent periods (remissions). Relapses cor-
relate with the formation of perivascular inflammatory le-
sions, or plaques, in the CNS. There has been no consistent
evidence of an active viral or other microbial infection in the
CNS of individuals with MS that would justify a local im-
mune response. In fact, it is widely believed that relapsing
remitting multiple sclerosis (RRMS) is initiated by an ab-
errant autoimmune attack directed against proteins embed-
ded in the myelin sheath. An autoimmune etiology of MS is
supported by extensive circumstantial evidence from animal
models and gene-wide association studies (GWAS) (Stein-
man and Zamvil 2006; Sawcer and others 2011), and by the
putative mechanism of the action of disease-modifying
agents (DMA) that suppress clinical relapses by targeting
lymphocytes (Stu¨ve 2008; Kowarik and others 2011). Early
in the disease course, peripheral blood leukocytes cross the
blood–brain barrier (BBB) and infiltrate the brain, spinal
cord, and optic nerves to drive plaque formation. Neurolo-
gical deficits emerge when plaques occur in ‘‘eloquent’’
areas. Natural history studies have shown that the incidence
of relapses and periodic breaches in the BBB decrease with
disease duration. However, the majority of individuals with
RRMS ultimately enter a secondary progressive (SP) stage,
characterized by a gradual, inexorable accumulation of
neurological disability that occurs independent of clinical
relapses. The molecular and cellular basis for this transition
is unclear, and the role of inflammation during the SP stage
is a subject of active debate.
Clinical trials of DMA in RRMS frequently use annual-
ized clinical relapse rates and magnetic resonance imaging
(MRI) parameters that correlate with new lesion formation
as primary outcome measures. The expanded disability
status scale (EDSS) is the most commonly employed mea-
sure of clinical progression. However, the EDSS has been
criticized for its poor intra- and inter-rater reliability and
low sensitivity once patients develop difficulty with ambu-
lation (Noseworthy and others 1990). As of now, no sero-
logical or peripheral blood mononuclear cell (PBMC)-based
biomarkers have been identified that reproducibly correlate
with clinical or radiological disease activity or progression.
Furthermore, no immunological assays have been developed
that are predictive of the subsequent clinical course or re-
sponsiveness to individual DMA. The discovery of such
biomarkers would greatly facilitate the clinical management
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of individuals with MS and provide power for smaller and
shorter clinical trials in the future.
In this article, we discuss the literature on immunolog-
ical biomarkers in MS with a focus on stage-specific dif-
ferences and similarities. There is accumulating evidence
that the nature of immune dysregulation evolves during
the course of MS. The presence of widespread microglial
activation in macroscopically normal appearing white
matter (Kutzelnigg and others 2005) and lymphoid folli-
cles in the leptomeninges (Serafini and others 2004) of
secondary progressive MS (SPMS) brains suggests an on-
going participation of neuroinflammation in the pathogenic
process, perhaps via pathways that are distinct from those
dominant in the relapsing-remitting (RR) phase. The rela-
tive importance of different immune cell subsets and
proinflammatory mediators during RRMS and SPMS holds
important implications regarding strategic approaches to
biomarker discovery and drug development across patient
cohorts.
The Immunopathogenesis of RRMS
Histological trademarks of acute MS lesions include
perivascular inflammatory infiltrates with adjacent demye-
lination and axonal transections (Adams and others 1989;
Lassmann 2010). The perivascular infiltrates are composed
of CD4 + and CD8 + lymphocytes and myeloid cells. GWAS
implicate CD4 + T cells in the development of MS. The
genetic locus that correlates most strongly with disease
susceptibility encodes major histocompatibility complex
(MHC) Class II molecules which govern CD4 + T-cell ac-
tivation (Sawcer and others 2011). Other genetic polymor-
phisms associated with susceptibility to MS encode
receptors that drive T-cell proliferation and survival, namely
the interleukin-2 (IL-2) receptor a chain and IL-7 receptor a
chain (Zuvich and others 2010; Wang and others 2011). The
animal model, experimental autoimmune encephalomyelitis
(EAE), provides further support for a critical role of CD4 +
T cells in autoimmune demyelination. EAE has striking
histological and clinical similarities with MS. It has been
induced in a wide variety of mammalian species by vacci-
nation against MHC Class II restricted myelin epitopes.
EAE can also be transferred from myelin-vaccinated mice to
syngeneic naı¨ve hosts using purified CD4 + T-cell lines or
clones (Sakai and others 1986; Fallis and others 1989).
Encephalitogenic myelin-specific CD4 + T cells invariably
fall within the Th1 or Th17 lineage and produce the
proinflammatory cytokines interferon g (IFNg) and IL-17,
respectively (Kroenke and others 2008).
Perhaps the most direct demonstration of the autoimmune
basis of RRMS comes from clinical trials of immunomodu-
latory agents. Martin and colleagues treated RRMS patients
with an altered peptide ligand (APL) of myelin basic protein
(MBP) with the intention of tolerizing MBP-reactive T cells
or deflecting their differentiation toward an immunosup-
pressive, regulatory, or an innocuous Th2 phenotype. Un-
expectedly, administration of the APL was temporally
associated with the expansion of circulating MBP-reactive
Th1 cells and clinical worsening in a subgroup of patients
(Bielekova and others 2000). Conversely, drugs that impede
lymphocyte trafficking to the CNS (Polman and others 2006;
Cohen and others 2010), block growth factor signaling into T
lymphocytes (Gold and others 2013), or deplete lymphocytes
from the periphery (Coles and others 2012) suppress MS
relapse rates and the accumulation of MRI lesions.
Dysregulation of Adaptive Immunity in RRMS:
The Myelin-Reactive T-Cell Repertoire
Earlier studies on the frequency of myelin-reactive T cells
in MS are conflicting; some investigators report a signifi-
cantly higher incidence of myelin-specific PBMC in indi-
viduals with MS compared with age- and gender-matched
healthy controls (HC), while others report no significant
difference (de Rosbo and Ben-Nun 1998; Diaz-Villoslada
and others 1999; Moldovan and others 2003; Bielekova and
others 2004; Moldovan and others 2005; Grau-Lo´pez and
others 2009). Many of the earlier studies that found no
differences between patients and HC used proliferation as a
measure of T-cell reactivity, and nonhuman myelin proteins
for antigenic stimulation. In contrast, Hedegaard and others
(2008) found that human MBP-reactive PBMC from un-
treated RRMS patients produced larger quantities of IFNg
and TNFa, and lower amounts of IL-10, than analogous
PBMC from HC. The production of IL-5 and IL-17 corre-
lated with the number of active plaques on MRI. Consistent
with these results, Moldovan and others (2003) detected
relatively high frequencies of PBMC in RRMS patients who
produced IFNg on ex vivo stimulation with libraries of
overlapping 9-mer peptides spanning the length of human
MBP. IFNg responses to proteolipid protein (PLP) peptides
correlated with the level of clinical disability. However, not
all discrepancies can be attributed to technical and method-
ological inconsistencies. Hence, Hellings and others (2001)
found no significant difference between MS patients and HC
in IFNg responses to human myelin oligodendrocyte protein
(MOG), MBP, or myelin peptides, despite using the same
immunological assay (enzyme linked immunosorbent spot, or
ELISPOT) as the former 2 studies.
A relatively small number of longitudinal analyses have
been performed in which fluctuations in cytokine production
were compared with radiological and/or clinical disease ac-
tivity. Calabresi and others (1998) followed 8 clinically active
RRMS patients with 6 monthly MRI scans and concomitant
ELISPOT assays. Changes in phytohemaglutanin-stimulated
IL-2 production correlated strongly with the appearance of
gadolinium-enhancing lesions. There was a weaker associa-
tion between enhancing MRI lesions and the frequency of
IFNg or Lymphotoxin-a secreting cells. Arbour and others
(2003) used a flow cytometry assay to monitor the activities
of T cells that are reactive to myelin-associated oligoden-
drocytic basic protein (MOBP) in 10 untreated RRMS pa-
tients over 18 months. MOBP-specific T-cell proliferation
and IFNg production correlated with clinical relapses and
enhancing lesions. Hellings and others (2002) monitored T-
cell reactivity to 3 myelin proteins (human MBP, PLP, and
MOG) in 7 patients with RRMS every 2 months over an 18
month period. In some patients, the appearance of gadoli-
nium-enhancing MRI lesions concurred with increased reac-
tivity to one or more myelin antigens as measured by IFNg
ELISPOT (Correale and others 1995). Increases in the se-
cretion of IL-6, TNFa, and IFNg by PBMC in response to
challenge with MOG or MBP (measured in culture superna-
tants by ELISA) generally coincided with MRI activity and
preceded clinical relapse. In contrast, a decrease in IL-10
production consistently preceded the occurrence of a clinical
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attack. Of note, 6 of the 7 patients were treated with IFNb-1a
during the study, which might have altered cytokine re-
sponses. More recently, Moldovan and others (2005) col-
lected blood samples from 14 RRMS patients and 15 age- and
sex-matched HC every 3 months over 1 year. MRI scans were
obtained at each visit. ELISPOT assays were performed using
MBP and PLP peptides spanning the whole molecule as the
antigenic stimulus. The majority of MS patients showed re-
current spikes in the frequency of MBP- and PLP-reactive
IFNg producers. This was particularly true for patients who
had gadolinium-enhancing lesions on serial MRI scans. In
contrast, IFNg responses were relatively stable in the HC
cohort. Periodic surges of anti-myelin T-cell reactivity in
PBMC from RRMS patients have also been reported by other
groups (Pender and others 2000).
Increased Frequencies of IL-171IFNc1
Co-Expressing T Cells in MS
Shortly after the IL-23 p19 chain was cloned in 2000
(Oppmann and others 2000), IL-17-producing cells were
detected in the CNS of animals with EAE and humans with
MS (Langrish and others 2005; Tzartos and others 2008).
Subsequently, IL-23-modulated Th17 cells received a great
deal of attention as putative effectors in autoimmune de-
myelinating disease. More recently, IL-17 + IFNg+ double
producers have been implicated in the pathogenesis of EAE
and MS (Hirota and others 2011). The frequency of IL-17 +
T cells in human PBMCs is very low to undetectable when
measured by intracellular staining and flow cytometry di-
rectly ex vivo or after short-term activation in the absence of
polarizing factors. In order to enumerate CD4 + T cells in
the circulation with the potential to produce IL-17, investi-
gators have taken to activating PBMC under Th17 polarizing/
stabilizing conditions for several days before analysis. Kebir
and others (2009) isolated CD4 +CD45RO + memory T cells
from peripheral blood of female RRMS patients and HC, and
incubated them with recombinant IL-23 and neutralizing
antibodies against IL-4 and IFNg. After 6 days, the cells were
harvested and subjected to flow cytometric analysis. The
frequency of IL-17+ and of IL-22+ lymphocytes, as well as
the percentage of cells simultaneously producing IL-17 and
IL-22, was elevated in T cell lines derived from RRMS pa-
tients during a clinical exacerbation when compared with
patients in remission or HC. Similarly, the frequency of
CD4+ T cells co-expressing IL-17 and IFNg was higher in
RRMS patients in relapse. In contrast, there was no difference
in the frequency of IFNg single producers between the
groups. Darlington and others (2013) employed a similar
approach to measure Th responses in individuals with ag-
gressive RRMS before and after treatment with ablative
chemotherapy and autologous hematopoietic stem cell
transplantation. PBMC were cultured for 6 days with anti-
CD3 antibodies, with or without recombinant IL-23, anti-
IFNg, and anti-IL-4, before surface and intracellular staining
and flow cytometry. The investigators found that a favorable
clinical response to treatment was associated with a diminu-
tion in the frequency of circulating Th17, but not Th1, cells.
Changes in Cytokine Expression
After Treatment with DMA
A number of studies have documented alterations in se-
rum cytokine levels after the initiation of disease-modifying
therapy (Navikas and Link 1996). Dhib-Jalbut and others
(2013) measured cytokine responses in patients with clini-
cally isolated syndrome and recent onset RRMS (less than
12 months from diagnosis) before and after the initiation of
high-dose beta interferon therapy. Samples of sera and/or
anti-CD3/CD28-stimulated PBMC culture supernatants were
analyzed for expression of a panel of pro-inflammatory and
regulatory cytokines by ELISA. Levels of IFNg (in both sera
and culture supernatants) and TNFa (in serum) fell after
initiation of the DMA. Conversely, there were significant
increases in IL-10 (in serum) and TGF-b (in serum) over the
12-month study period. Expression of the Th2-associated
cytokine IL-13 rose in culture supernatants. Surprisingly,
IL-17 levels remained stable in culture supernatants after the
initiation of beta interferon. However, IL-17 levels were
higher in patients who had breakthrough relapses compared
with those who were relapse free throughout the study.
Several independent laboratories have similarly detected
systemic elevations in IL-10 expression in individuals with
RRMS after the administration of beta interferon (Rudick
and others 1998; Waubant and others 2001; Kvarnstro¨m and
others 2013). Recently, Ayers and others (2013) showed that
lipopolysaccharide (LPS)-stimulated CD14 + monocytes up-
regulate IL-10 within hours of the first dose of glatiramer
acetate.
Evidence of a Role of Inflammation in SP Phase
As mentioned earlier, the formation of gadolinium-
enhancing MRI lesions, indicative of local BBB breakdown
and associated perivascular inflammation, decreases in fre-
quency with disease duration and is less common in indi-
viduals with SPMS than RRMS (Filippi and others 1997).
Furthermore, immunomodulatory DMA tend to lose efficacy
after transition to a SPMS stage (Paolillo and others 1999;
Panitch and others 2004). Such observations have led to the
proposal that the gradual accumulation of disability in
SPMS is driven by neurodegeneration, manifested as neu-
ronal cell death, Wallerian degeneration, and astrogliosis,
independent of the autoimmune assault which predominates
earlier in the disease course (Trapp and Nave 2008).
Conversely, a substantial body of data indicates that in-
flammation is still relevant, and contributes to CNS tissue
damage, during the SP stage. We and others have found
increased frequencies of circulating Th1 and Th17 cells in
individuals with SPMS as well as RRMS compared with
age- and sex-matched HC (unpublished data (Becher and
others 1999). Neuropathological studies demonstrate wide-
spread microglial activation and diffuse lymphocyte infil-
tration in the cerebral white matter of individuals with
SPMS, as opposed to the multifocal, lymphocyte-rich peri-
vascular infiltrates that are characteristic of the RR stage
(Kutzelnigg and others 2005; Frischer and others 2009).
Prineas originally documented the presence of perivascular
infiltrates ‘‘.organized in a manner similar to the antibody-
producing medullary region of lymph nodes’’ in the brains
of individuals with progressive MS (Prineas 1979). More
recently, Serafini and others (2004) discovered lymphoid
follicles in the sulci of brain specimens from patients with
SP, but not RR, MS. The earlier observations indicate that
the nature of the aberrant immune response evolves over the
disease course and might explain why the efficacy of indi-
vidual DMA differs between the RR and SP phases.
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Dysregulation of the Innate Immune
System in SPMS
Multiple studies point to dysregulation of the innate
arm of the immune system (and in particular, cells of the
myeloid/granulocyte lineage) as a distinctive feature of
SPMS. Hence, Filion and others (2003) found increased
expression of costimulatory molecules on peripheral blood
monocytes from SPMS patients compared with those from
RRMS or HC. Freshly isolated monocytes from SPMS pa-
tients secreted 10-fold more IL-12 than monocytes from
either RRMS patients or HC. Karni and others (2006) de-
tected an increased percentage of monocytes expressing IL-
12, CD80, and TNFa in the blood of SPMS patients. PBMC
from SPMS patients, by comparison to PBMC from RRMS
patients or HC, also produced larger amounts of the myeloid
chemokine, IL-18, in response to polyclonal stimulation
with aCD3 and aCD28 (Karni and others 2002). Elevated
IL-18 production was dependent on the interaction between
antigen-presenting cells and activated T cells via CD40-
CD40 ligand engagement. Within the SPMS cohort, IL-18
levels correlated with disease duration. More recently, it was
shown that purified myeloid dendritic cells from SPMS
patients secrete larger quantities of IL-12 in response to
IFNg or LPS than dendritic cells from patients with RRMS
or from HC (Karni and others 2006). Myeloid dendritic cells
from SPMS patients were particularly efficient at priming
naı¨ve T cells to produce proinflammatory cytokines. Col-
lectively, these data suggest that the transition from RR to
SPMS is mirrored by a shift from adaptive to innate im-
munity (Weiner 2008). In a recent study, an increased fre-
quency of IL-23 receptor expressing CD4 + T cells was
detected in peripheral blood from SPMS patients when
compared with RRMS patients (Christensen and others
2013). IL-23 receptor is a marker of Th17 cells. The accu-
mulation of Th17 cells during SPMS could, potentially,
drive innate immune dysregulation, as a major function of
IL-17 is to induce the production of chemokines and growth
factors that mobilize and activate myeloid cells (Iwakura
and others 2011).
Lymphoid Chemokines and Progressive MS
The discovery of lymphoid follicle-like structures in the
meninges of autopsied brain tissue from individuals with
SPMS has prompted renewed interest in the role of neu-
roinflammation during the SP phase. The lymphoid ag-
gregates, found in *40% of SPMS autopsy specimens,
contained proliferating B cells, T cells, and plasma cells,
and a reticulum of CD35 + stromal cells and follicular den-
dritic cells expressing the lymphoid chemokine, CXCL13
(Serafini and others 2004; Magliozzi and others 2007).
Follicular plasma cells and plasmablasts expressed surface
immunoglobulin. Similar structures were not found in a
series of brains from individuals with RRMS and primary
progressive MS. The presence of meningeal follicles was
associated with a younger age of MS onset, a more ag-
gressive clinical course, more pronounced demyelination,
microglial activation, and loss of neurites in the cerebral
cortex. Each meningeal follicle was located adjacent to a
large subpial cortical lesion. The authors hypothesized that
the meningeal follicles have a direct role in cortical injury,
possibly by releasing soluble factors that diffuse into the
underlying cortex and have toxic effects on glia and neu-
rons/axons (Magliozzi and others 2007).
Substances produced by leukocytes in meningeal folli-
cles, such as lymphoid chemokines, are candidate bio-
markers in MS. In fact, CXCL13 is expressed at elevated
levels in cerebrospinal fluid (CSF) from patients with
SPMS, as well as from patients with RRMS in relapse, when
compared with patients with noninflammatory neurological
diseases (Krumbholz and others 2006; Festa and others
2009; Sellebjerg and others 2009; Piccio and others 2010;
Khademi and others 2011; Ragheb and others 2011; Biele-
kova and others 2012; Alvarez and others 2013; Romme
Christensen and others 2013). CSF CXCL13 levels repro-
ducibly correlate with leukocyte count and IgG index
(Krumbholz and others 2006; Sellebjerg and others 2009;
Ragheb and others 2011). In one study, CSF CXCL13 levels
correlated with levels of the neurofilament light chain (a
marker of axonal damage), specifically in the progressive
MS cohort (Romme Christensen and others 2013). When
CSF samples were collected from SPMS patients 1 year
apart, CXCL13 levels tended to be stable (Romme Chris-
tensen and others 2013).
T-follicular helper (Tfh) cells are a subset of CD4 +
T cells that interact with B cells in lymphoid follicles and
participate in germinal center formation. Flow cytometric
studies revealed an increased percentage of CD4 + T cells
with a cell surface phenotype consistent with activated Tfh
(ie, CXCR5 + ICOS + ) in PBMC from patients with pro-
gressive MS (Christensen and others 2013). Interestingly,
the frequency of circulating Tfh cells and DC-SIGN + B
cells correlated with accumulation of disability in SPMS
patients (defined by a significant increase in EDSS score
over the previous 2 years). Whether Tfh cells migrate to the
CNS and participate in the development of meningeal fol-
licles remains to be elucidated.
Challenges to the Discovery
of Biomarkers in MS
Despite the advances that have been made in our under-
standing of MS pathogenesis, it has been difficult to trans-
late that knowledge into the discovery of clinically useful
biomarkers. There are many explanations for this. First and
foremost, biomarker discovery is hindered by the inacces-
sibility of nervous system tissues for cellular and molecular
analysis. The inflammatory molecules and immune cells
present in CSF do not necessarily reflect pathological pro-
cesses in the CNS parenchyma. Furthermore, it is imprac-
tical to obtain multiple CSF samples for serial monitoring.
Serum assays and PBMC analyses are even further removed
from immune responses within the CNS. In addition, pe-
ripheral immune parameters are vulnerable to a multitude of
extraneous factors (such as infections, vaccinations, and
allergies) that could complicate data interpretation.
The ideal biomarker would be specific for CNS autoim-
munity. Based on our understanding of MS pathogenesis,
it would involve a measurement of myelin antigen-specific
T-cell responses. However, the identification of a dominant
myelin epitope that is targeted in a majority of MS patients
is far from trivial. There is likely to be considerable inter-
subject variability even within subpopulations bearing the
same MHC Class II haplotype. With the advent of epi-
tope spreading, the myelin-reactive repertoire might evolve
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within individuals over time. Finally, autoreactive T cells in
the periphery could differ in phenotype and/or antigenic
reactivity from the effector cells that are actually responsi-
ble for neuroinflammation and CNS tissue damage, if the
latter are sequestered behind the BBB.
Drawing correlations between immune parameters and
disease activity poses additional challenges. MRI studies
have shown that the majority of MS lesions form silently.
Therefore, imaging is a more accurate barometer of new
lesion formation than clinical signs or symptoms. However,
even MRI may be insufficient. The sensitivity of MRI in
detecting new lesions depends on the magnet strength, the
dose of gadolinium administered, and the time lapse be-
tween administration of gadolinium and image acquisition
(Uysal and others 2007; de Graaf and others 2012). Mag-
netization transfer and MR spectroscopy have revealed
pathological changes in regions of MS brains that resemble
‘‘normal appearing white matter’’ on conventional MRI.
The use of imaging modalities as a gold standard for vali-
dating biomarkers is particularly problematic in progressive
MS, as cortical lesions, axonal changes, and meningeal
follicles are the most difficult to visualize.
Future progress will likely be advanced by longitudinal
studies with large cohorts of demographically uniform pa-
tients followed over long periods of time with multimodal
imaging and clinical assessment tools (including cognitive
testing). It is essential that the subject populations be rigor-
ously characterized with regard to clinical, radiological, and
genetic characteristics as well as treatment history. Auo-
tantigen-specific assays should involve libraries of over-
lapping peptides that span the length of several candidate
myelin proteins. When possible, serum and CSF parameters
should be assayed in parallel. Novel assays in proteomics
(including secretomics), flow cytometry, genomics, and
epigenetics will hopefully yield more reliable and clinically
meaningful biomarkers.
Conclusion
Based on the immunological and neuropathological studies
summarized earlier, we would argue that the collective data
support a persistent role of inflammation across the clinical
stages of MS. However, the cytokine/chemokine networks,
leukocyte subsets, and anatomical staging of the autoimmune
response appear to evolve over time. In early stages after
initial clinical presentation, pathology is driven by an immune
assault mounted from the periphery. Lymphocytes and my-
eloid cells infiltrate CNS white matter from the circulation
and trigger an inflammatory cascade that, ultimately, results
in numerous defined areas of demyelination and axonopathy,
centered around parenchymal venules. During this period,
systemic administration of agents that hinder lymphocyte
egress from lymph nodes (ex. fingolimod), block lymphocyte/
monocyte trafficking across the BBB (ex. natalizumab), or
deplete circulating lymphocytes (ie, alemtuzumab) is effec-
tive in suppressing clinical relapses.
In contrast, in the SP phase of disease, the ‘‘headquar-
ters’’ of the autoimmune assault shift to the target organ
itself, manifested by widespread microglial activation and
astrogliosis and the development of meningeal lymphoid
follicles in the deep recesses of the brain. The mechanism
underlying this transformation is poorly understood. To
some extent, the immunopathology of SPMS resembles an
amplification of the dysregulation that occurs in the earlier
RR stage. Innate immune cells that are activated by, and act
downstream of, myelin-reactive T cells show striking ab-
normalities in SPMS. IL-17- as well as IFNg-producing
T cells have been implicated in pathogenesis throughout the
disease course. IL-17 induces the production of chemokines
and growth factors that activate myeloid cells and trigger
their mobilization into the circulation (Ouyang and others
2008). In addition, myelin-reactive Th17 cells induce ec-
topic follicle-like structures in the CNS in mice with
adoptively transferred EAE (Peters and others 2011). In-
terestingly, the frequency of circulating IL-23 receptor ex-
pressing CD4+ T cells, suggestive of a Th17 phenotype,
associates with MS disease duration and is preferentially el-
evated during SPMS (Christensen and others 2013). Con-
sistent with this observation, a high frequency of circulating
RORgt+ CD4+ T cells was recently found in individuals
with SPMS, but not RRMS (Gironi and others 2013). It will
be interesting to reproduce these studies in independent
cohorts and to examine, in greater detail, the relative im-
portance of autoreactive Th1 and Th17 cells, and down-
stream innate immune factors, during the different stages of
MS. The discovery of serological and CSF biomarkers that
reflect CNS disease activity, and predict future clinical
phenomenology and responsiveness to DMA, is an imme-
diate goal for advancing MS therapeutics to the next level.
Perhaps most important will be the identification of candi-
date therapeutic targets for progressive forms of MS.
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